Weekend ESMO melanoma details extend Moderna’s valuation reset

 

• Moderna’s October 24 ESMO presentation formally confirmed INTerpath-001’s detailed Phase 3 results.
• Intismeran reduced recurrence or death risk 42% and metastasis or death 38%.
• Reuters and analysts characterized Thursday’s initial collapse as an expectations-driven sell-the-news reversal.
• Shares fell 17.6% Thursday and 1.25% Friday, satisfying the continuation pattern.
• Weekend Wall Street Journal analysis questioned valuation, pricing, and success beyond melanoma.
• No newer SEC filing, company release, or analyst action surfaced by 6:30 ET.
• Merck, BioNTech, Pfizer, and XBI were down only about 1%-2% premarket.
• The 9.52% decline matches Moderna’s 10.1% monthly range, below its weekly range.

https://finviz.com/stock?t=MRNA&p=d